ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Study Purpose

A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years - 75 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Age ≥18 years, and ≤75 years, male or female; - Eastern Cooperative Oncology Group (ECOG) performance status of 0~2; - Breast cancer patients diagnosed as HR arbitrary/HER2-positive by pathological examination; - Metastatic breast cancer subjects previously treated with trastuzumab, taxane and EGFR-TKI-containing regimens; - MRI confirmed brain metastasis with at least one intracranial parenchymal untreated metastatic lesion; - Mannitol, bevacizumab, or hormone therapy is allowed before enrollment; - Adequate organ functions; - Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1.

- Patients who participate in the trial voluntarily, sign an informed consent, have good compliance and are willing to comply with the follow-up visit.

Exclusion Criteria:

- Pneumomeningeal metastases or cystic metastases confirmed by MRI or lumbar puncture; - Uncontrolled third space effusion; - Previous treatment with T-DM1 or other HER2-ADC drugs; - Received a whole-brain radiotherapy, chemotherapy, or surgery within 2 weeks prior to the first dose of ARX788, or trastuzumab-targeted therapy or endocrine therapy within 1 week, or palliative radiotherapy for bone metastases within 2 weeks; - Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease; - Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention; - Unwilling or unable to stop wearing contact lenses for the duration of the study; - Participated in other clinical trials within 2 weeks prior to enrollment; - Receiving any antitumor therapy for any other tumor, bevacizumab for the control of brain edema and bisphosphonates for the treatment of bone metastases or the prevention of osteoporosis are the exception; - With a history of any malignancies other than breast cancer in the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin or squamous cell carcinoma of the skin; - Cardiac insufficiency; - Uncontrolled hypertension; - History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments; - Pregnancy or lactation; - History of immunodeficiency, including HIV-positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; - Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis; - History of neurological or psychiatric disorder, including epilepsy or dementia; - Suffering severe or uncontrolled systemic diseases.

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05018702
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 2
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Fudan University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	China
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	HER2-positive, Metastatic Breast Cancer

Additional Details

This is an open-label, single arm, phase 2 study of ARX788 in HER2-positive, metastatic breast cancer patients whose disease is resistant or refractory to TKI. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion. In this study, Simon's two-stage design is used. Subjects received treatment until disease progression, intolerable toxicity, withdrawal from the study, or discontinuation judged by the investigator. Drug efficacy and safety data will be collected.

Arms & Interventions

Arms

Experimental: ARX788

Interventions

Drug: - ARX788

1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.